MIRM
NasdaqMirum Pharmaceuticals, Inc.
Basic Materials · Pharmaceutical Preparations
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
$19.1M
2021
$77.1M
2022
$186.4M
2023
$336.9M
2024
$521.3M
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$521.3M
Net Income$-23.4M
Gross Profit—
Oper Income$-22.1M
EPS (dil)$-0.47
Rev/sh$8.55
FCF/sh$0.90
Book/sh$5.16
Gross M—
Oper M-4.2%
Profit M-4.5%
FCF M10.5%
ROE-7.4%
ROA-2.8%
ROIC-134.0%
R&D/Rev—
Rev Y/Y54.7%
Rev 3Y CAGR89.1%
EPS Y/Y74.6%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y+5.6%
Current Ratio2.67
Quick Ratio2.55
Debt/Eq—
Int Coverage-1.5×
Net Debt—
Total Debt—
Cash & Eq$296.7M
Total Assets$842.8M
Oper CF$55.8M
Capex$954,000
Free CF$54.9M
Buybacks—
Equity$314.7M
Liabilities$528.1M
Shs Outstand0.06B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $19.1M | $77.1M | $186.4M | $336.9M | $521.3M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $-173.4M | $-131.2M | $-109.2M | $-87.6M | $-22.1M |
| Net Income | $-84.0M | $-135.7M | $-163.4M | $-87.9M | $-23.4M |
| Diluted EPS | $-2.77 | $-4.02 | $-4.00 | $-1.85 | $-0.47 |
| Operating Cash Flow | $-132.8M | $-120.1M | $-70.9M | $10.3M | $55.8M |
| Free Cash Flow | $-132.8M | $-120.4M | $-71.1M | $9.3M | $54.9M |
COMMUNITY · $MIRM0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.